Publications by authors named "S Ohue"
This study aims to elucidate the clinical and molecular characteristics, treatment outcomes and prognostic factors of patients with histone H3 K27-mutant diffuse midline glioma. We retrospectively analyzed 93 patients with diffuse midline glioma (47 thalamus, 24 brainstem, 12 spinal cord and 10 other midline locations) treated at 24 affiliated hospitals in the Kansai Molecular Diagnosis Network for CNS Tumors. Considering the term "midline" areas, which had been confused in previous reports, we classified four midline locations based on previous reports and anatomical findings.
View Article and Find Full Text PDFArticle Synopsis
- * BCNU concentrations peaked one hour after surgery, decreased quickly within 24 hours, and remained elevated for about a week, with early recurrence (ER) patients showing slightly lower AUC compared to those with late or no recurrence (LN), though not significantly.
- * MRI results indicated all ER patients had highly invasive GBMs, while all LN patients had less-invasive types, suggesting that higher BCNU concentrations might aid survival in less-invasive GBM, despite no overall correlation with tumor progression or
Article Synopsis
- Glioblastoma multiforme (GBM) has a poor prognosis primarily due to the presence of invasive glioma stem-like cells (GSCs) that adapt their behavior in response to their environment during tumor recurrence.
- *Severe hypoxia enhances the expression of CD44, promoting GSC invasiveness, while moderate hypoxia increases osteopontin levels, which inhibits GSC migration and encourages proliferation, shifting the GSCs to a less invasive state.
- *The interplay between CD44 and osteopontin, driven by varying oxygen levels, is crucial for GSC behavior; targeting both factors could provide an effective therapeutic strategy to improve outcomes in GBM patients.*
Antiangiogenic therapy with bevacizumab (Bev), a monoclonal antibody targeting vascular endothelial growth factor (VEGF), is a common treatment for recurrent glioblastoma (GBM), but its survival benefit is limited. Resistance to Bev is thought to be a major cause of ineffectiveness on Bev therapy. To optimize Bev therapy, identification of a predictive biomarker for responsiveness to Bev is required.
View Article and Find Full Text PDF